Piramal Pharma Ltd vs Zim Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Piramal Pharma Ltd is ₹ 163.85 as of 12 Jun 15:30 . The P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 0 on March 2026 . This represents a CAGR of -100.00% over 3 yearsThe P/E Ratio of Zim Laboratories Ltd changed from 16.1 on March 2021 to 54.9 on March 2026 . This represents a CAGR of 22.68% over 6 years The Market Cap of Piramal Pharma Ltd changed from ₹ 8165 crore on March 2023 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 4 yearsThe Market Cap of Zim Laboratories Ltd changed from ₹ 117.75 crore on March 2021 to ₹ 320.31 crore on March 2026 . This represents a CAGR of 18.15% over 6 years The revenue of Piramal Pharma Ltd for the Mar '26 is ₹ 2811 crore as compare to the Dec '25 revenue of ₹ 2193 crore. This represent the growth of 28.18% The revenue of Zim Laboratories Ltd for the Mar '26 is ₹ 111.44 crore as compare to the Dec '25 revenue of ₹ 110.36 crore. This represent the growth of 0.98% The ebitda of Piramal Pharma Ltd for the Mar '26 is ₹ 344.37 crore as compare to the Dec '25 ebitda of ₹ 208.12 crore. This represent the growth of 65.47% The ebitda of Zim Laboratories Ltd for the Mar '26 is ₹ 13.35 crore as compare to the Dec '25 ebitda of ₹ 14.51 crore. This represent the decline of -7.99% The net profit of Piramal Pharma Ltd changed from ₹ -88.64 crore to ₹ -8.83 crore over 8 quarters. This represents a CAGR of -68.44% The net profit of Zim Laboratories Ltd changed from ₹ 0.9 crore to ₹ 3.74 crore over 8 quarters. This represents a CAGR of 103.85% The Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 0 % on March 2026 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Zim Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Piramal Pharma Ltd

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

About Zim Laboratories Ltd

Zim Laboratories Limited was incorporated in February, 1984 under the name and style of Zim Laboratories Private Limited in Maharashtra.
The Company became a Public Limited Company through fresh Certificate of Incorporation issued by the Registrar of Companies, Mumbai.
The Company commenced its operations in 1989 and is a specialist firm focused on the developing, manufacturing, and global distribution of differentiated generic Pharmaceutical and Nutraceutical products in oral solid dosage forms.
The Company's comprehensive services include both PreFormulation Intermediates (PFI) and Finished Formulations (FF) across numerous vital therapeutic areas globally. Company's core therapeutic focus areas include: Urology, Gastrointestinal, NSAIDs / Analgesics, Anti-infectives, Cardiovascular, Central Nervous System, and Vitamins & Supplements.

FAQs for the comparison of Piramal Pharma Ltd and Zim Laboratories Ltd

Which company has a larger market capitalization, Piramal Pharma Ltd or Zim Laboratories Ltd?

Market cap of Piramal Pharma Ltd is 21,814 Cr while Market cap of Zim Laboratories Ltd is 604 Cr

What are the key factors driving the stock performance of Piramal Pharma Ltd and Zim Laboratories Ltd?

The stock performance of Piramal Pharma Ltd and Zim Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Piramal Pharma Ltd and Zim Laboratories Ltd?

As of June 14, 2026, the Piramal Pharma Ltd stock price is INR ₹163.85. On the other hand, Zim Laboratories Ltd stock price is INR ₹112.95.

How do dividend payouts of Piramal Pharma Ltd and Zim Laboratories Ltd compare?

To compare the dividend payouts of Piramal Pharma Ltd and Zim Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.